Telios Pharma

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Telios Pharma sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 4 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Telios Pharma: 8 sponsored US clinical trials, 4 recruiting.

Telios Pharma sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 2 trials.

Upper-quartile sponsor footprint

Telios Pharma sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

NCT07220408
RECRUITING Phase 2

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472
RECRUITING Phase 1

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509
RECRUITING Phase 2

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

NCT04655118
ACTIVE NOT RECRUITING Phase 2

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

NCT06225973
COMPLETED Phase 2

A Study Of TL-925 For The Treatment of AC

NCT06293820
COMPLETED Phase 2

A Study of TL-925 as a Treatment for Dry Eye Disease

NCT05745064
COMPLETED Phase 1

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

NCT04419623

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6

Therapeutic Areas

Dry Eye Disease 2
Allergic Conjunctivitis 2
Myelofibrosis 2
Post-ET Myelofibrosis 1
Post-PV MF 1
Indolent Systemic Mastocytosis 1
Primary Myelofibrosis 1

What is open in the Telios Pharma pipeline

4 recruiting of 8 indexed (50% open); 3 completed (38%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Dry Eye Disease (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Telios Pharma: open-pipeline peers nationwide

Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Telios Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0246810 0%20%40%60% Total trials Recruiting share Telios PharmaAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Telios Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Telios Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Telios Pharma page

8 registered trials is a research-attention snapshot, not an endorsement of Telios Pharma or any single study.

  • 4 of Telios Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dry Eye Disease is the condition Telios Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Telios Pharma pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.